Gene Editing: Exa-Cel Panel Review Raises Practical Concerns About Theoretical Risks

US FDA advisory committee members questioned how potential off-target effects with Vertex’s gene therapy for sickle cell disease should be conveyed to patients and families, and whether labeling should say anything about these theoretical risks.